MARKER THERAPEUTICS, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
MARKER THERAPEUTICS, INC. (MRKR) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2022-03-17
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-12-31 was $36.66K.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2020-09-30 was $1.89M.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $11.11M.
- MARKER THERAPEUTICS, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2019 was $0.00.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month as first filed | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month as first filed |
|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-17 | $0.00 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $0.00 10-Q · filed 2021-11-10 | ||||
| 2021-06-30 | $0.00 10-Q · filed 2021-08-10 | |||||
| 2020-12-31 | $36.66K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $1.93M derived: sum of 2 quarters · filed 2022-03-17 | $10.44M derived: sum of 3 quarters · filed 2022-03-17 | $11.11M 10-K · filed 2022-03-17 | ||
| 2020-09-30 | $1.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $10.41M derived: sum of 2 quarters · filed 2021-11-10 | $11.08M 10-Q · filed 2021-11-10 | $11.08M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $8.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $9.18M 10-Q · filed 2021-08-10 | $9.18M derived: sum of 3 quarters · filed 2021-08-10 | $9.18M derived: sum of 4 quarters · filed 2021-08-10 | ||
| 2020-03-31 | $670.00K 10-Q · filed 2020-05-11 | $670.00K derived: sum of 2 quarters · filed 2021-03-09 | $670.00K derived: sum of 3 quarters · filed 2021-03-09 | $1.34M derived: sum of 4 quarters · filed 2021-03-09 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | $670.00K derived: sum of 3 quarters · filed 2021-03-09 | $0.00 10-K · filed 2021-03-09 | $670.00K 10-K · filed 2020-03-12 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $670.00K derived: sum of 2 quarters · filed 2020-11-09 | $0.00 10-Q · filed 2020-11-09 | $670.00K 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | $670.00K 10-Q · filed 2019-08-09 | $0.00 10-Q · filed 2020-08-10 | ||||
| 2019-03-31 | $670.00K 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |